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 34 
Abstract 35 
 36 
The aggregation of α-synuclein, an intrinsically disordered protein that is highly abundant 37 
in neurons, is closely associated with the onset and progression of Parkinson's disease. We 38 
have shown previously that the aminosterol squalamine can inhibit the lipid induced 39 
initiation process in the aggregation of a-synuclein and we report here that the related 40 
compound trodusquemine is capable of inhibiting not only this process but also the fibril-41 
dependent secondary pathways in the aggregation reaction. We further demonstrate that 42 
trodusquemine can effectively suppress the toxicity of α-synuclein oligomers in neuronal 43 
cells, and that its administration, even after the initial growth phase, leads to a dramatic 44 
reduction in the number of α-synuclein inclusions in a Caenorhabditis elegans model of 45 
Parkinson's disease, eliminates the related muscle paralysis, and increases lifespan. On the 46 
basis of these findings, we show that trodusquemine is able to inhibit multiple events in the 47 
aggregation process of a-synuclein, and hence to provide important information about the 48 
link between such events and neurodegeneration, as it is initiated and progresses. We 49 
suggest, in addition, that trodusquemine has the potential to be a therapeutic candidate in 50 
Parkinson's disease and related disorders, for these effects as well for its ability to cross the 51 
blood brain barrier and promote tissue regeneration. 52 
 53 
 54 
 55 
 56 
The aggregation of a-synuclein, a 140-residue protein highly expressed in neuronal synapses1-5, 57 
is a hallmark of the pathogenesis of a variety of neurodegenerative disorders collectively known 58 
as a-synucleinopathies, including Parkinson’s disease (PD), PD with dementia, dementia with 59 
Lewy bodies, and multiple-system atrophy5-12. The mechanism of aggregation of a-synuclein is 60 
highly complex and is modulated by a variety of environmental factors, such as pH, temperature, 61 
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ionic strength, and the presence of co-solvents, and by its interactions with a range of cellular 62 
components, including lipid membranes13-20. In addition, the aggregation process is highly 63 
heterogeneous and leads to the formation of multiple types of fibrillar and pre-fibrillar species, 64 
the degree of polymorphism of which also depends on the experimental conditions21-26.  65 
 66 
Although it is challenging to study the mechanistic events associated with α-synuclein 67 
aggregation, a detailed understanding of this process is of considerable importance for the 68 
rational development and evaluation of potential therapeutics directed at reducing or eliminating 69 
the underlying sources of toxicity that lead to PD10,27,28, 29. The aggregation of a-synuclein has 70 
been shown to be enhanced dramatically by its binding to lipid membranes14,30; disrupting such 71 
interactions with small molecules therefore, has the potential to provide new information about 72 
the molecular processes involved in pathogenicity, and could also represent the basis for an 73 
effective therapeutic strategy. In this context, we have recently found that the aminosterol 74 
squalamine31-33 interferes with the binding of a-synuclein to membranes, reduces the initiation of 75 
its aggregation in vitro, and decreases the toxicity associated with such aggregation in human 76 
neuroblastoma cells and in a C. elegans model of PD29.  77 
 78 
The existence of additional natural aminosterol compounds related to squalamine33 prompted us 79 
to explore their effects on the formation and properties of a-synuclein aggregates in vitro and in 80 
vivo. One such compound, trodusquemine (also known as MSI-1436, Fig. S1a)32-34, belongs to a 81 
class of cationic amphipathic aminosterols that have been widely studied in both animal models 82 
and in clinical trials in relation to the treatment of cancer35, anxiety36, and obesity37,38. 83 
Trodusquemine was initially isolated from dogfish shark liver as a minor aminosterol along with 84 
six other related compounds, including squalamine33. Moreover, it has since been shown to be 85 
able to cross the blood brain barrier, a property of considerable importance for any therapeutic 86 
molecule for the treatment of neuropathic disorders31. In addition, trodusquemine has been 87 
shown to be able to stimulate regeneration in a range of vertebrate tissues and organs following 88 
injury with no apparent effect on uninjured tissues39 . Trodusquemine shares the same parent 89 
structure as squalamine, but with a spermine moiety replacing the spermidine on the side chain, 90 
resulting into an increased positive charge (Fig. S1a).  91 
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 92 
Given the structural similarity between trodusquemine and squalamine, and previous reports 93 
suggesting that the more positively charged trodusquemine is likely to enhance its ability to 94 
reduce negative electrostatic surface charges on intracellular membranes32,40, we set out to 95 
characterise the effects of trodusquemine on the aggregation kinetics of a-synuclein in vitro 96 
using experimental conditions previously used to study individual microscopic steps in the 97 
aggregation of a-synuclein in the absence of any aminosterol15,41.  98 
 99 
Our first studies of the effects of trodusquemine presented here were aimed to probe its effects 100 
on the initiation of a-synuclein aggregation in the presence of lipid vesicles14,15,30,41, on fibril 101 
elongation13,15,41 and on secondary nucleation13,15,41,42. We then explored the effects of 102 
trodusquemine on inhibiting the cytotoxicity of preformed oligomers of a-synuclein towards 103 
neuronal cells43. We also evaluated the effects of trodusquemine using a well-established 104 
transgenic C. elegans model of PD, in which a-synuclein forms inclusions over time in the large 105 
muscle cells leading to age-dependent paralysis29. 106 
 107 
 108 
Results and Discussion 109 
 110 
Trodusquemine inhibits both the lipid-induced initiation and the fibril-induced 111 
amplification steps of a-synuclein aggregation 112 
 113 
In order to characterize systematically the influence of trodusquemine on the microscopic events 114 
involved in the aggregation of a-synuclein, we employed a previously described three-pronged 115 
chemical kinetics strategy13,15,41,42. This approach involves the study of a-synuclein aggregation 116 
under a series of specifically designed conditions that make it possible to characterize separately 117 
the processes of heterogeneous primary nucleation14, fibril elongation13,15,41,42, and fibril 118 
amplification13,15,41,42, the latter including secondary processes such as fragmentation and 119 
surface-catalyzed secondary nucleation that result in the proliferation of aggregated forms of a-120 
synuclein.  121 
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 122 
First, we tested the influence of trodusquemine on the lipid-induced initiation of a-synuclein 123 
aggregation14,15. Using DMPS vesicles at 30 °C14, we observed that increasing concentrations of 124 
trodusquemine resulted in an increase in the diameter of the vesicles to above 100 nm for 125 
trodusquemine-to-lipid ratios above 0.2, as monitored by dynamic light scattering (Fig. S2a). We 126 
have shown previously that variations in the size of the vesicles below 100 nm does not affect 127 
the kinetics of aggregation of a-synuclein14, and so in the present study we carried out all kinetic 128 
and lipid-binding experiments at trodusquemine-to-lipid ratios below 0.2. a-Synuclein was 129 
therefore incubated at a variety of concentrations, ranging from 20 to 100 µM, in the presence of 130 
100 µM DMPS under quiescent conditions at 30 °C, and in the presence of concentrations of 131 
trodusquemine ranging from 0 to 10 µM. The aggregation reaction was monitored in real time 132 
using ThT fluorescence (Figs. S3 and S4), and we observed a dose-dependent inhibition of the 133 
lipid-induced aggregation of a-synuclein by trodusquemine, which was very similar to that 134 
observed in the presence of squalamine29.  135 
 136 
In the light of these results, we investigated the influence of trodusquemine on the lipid-binding 137 
properties of a-synuclein using far-UV circular dichroism (CD) spectroscopy. We incubated 5 138 
µM a-synuclein in the presence of 250 µM DMPS and increasing concentrations of 139 
trodusquemine (0-50 µM) (Fig. S2b-c). At the protein-to-lipid ratio used in these experiments, 140 
effectively all the protein molecules in the absence of trodusquemine are bound to the surface of 141 
DMPS vesicles in an a-helical conformation, as predicted from the binding constants previously 142 
determined for the a-synuclein-DMPS system14 (Fig. S2b). In the presence of increasing 143 
concentrations of trodusquemine, the CD signal of a-synuclein measured at 222 nm increases 144 
from a value characteristic of an a-helix to that of a random coil (Fig. S2c) indicating that 145 
trodusquemine, like squalamine, can displace a-synuclein from the surfaces of vesicles.  146 
 147 
We then analyzed these data using the competitive binding model that was used to describe the 148 
displacement of α-synuclein from vesicles by β-synuclein13,15,41 and by squalamine29, in which α-149 
synuclein and β-synuclein or squalamine compete for binding sites at the surface of the DMPS 150 
vesicles. This analysis allowed us to determine both the dissociation constant (KD,T) and 151 
 
6 
stoichiometry (LT) associated with the trodusquemine-DMPS system, KD,T  = 1.62 x 10-8 M and 152 
LT = 5.1 (Fig. S2c). In comparable experiments conducted with the squalamine-DMPS system, 153 
we found KD,S = 6.7 x 10-8 M and LS = 7.3, respectively29; the higher affinity for the anionic 154 
phospholipids by trodusquemine compared to squalamine is expected on the basis of the higher 155 
net positive charge of the former zwitterion. To characterize this inhibition in more detail we 156 
analyzed the early time points of the aggregation reaction (see Materials and Methods for 157 
details) by globally fitting a single-step nucleation model to the kinetic traces as previously 158 
described for squalamine14 (Figs. 1a,b, S4 and S5). This analysis is described in the SI and 159 
indicates that trodusquemine inhibits α-synuclein lipid induced aggregation via a somewhat more 160 
complex mechanism than that reported for squalamine. In particular, our analysis suggests that 161 
the mechanism involves not only the displacement of monomeric α-synuclein from the 162 
membrane, as observed for squalamine, but also the interaction with intermediate species on the 163 
aggregation pathway; indeed, such interactions could also contribute to the ability of 164 
trodusquemine to suppress the interaction of α-synuclein oligomers with cell membranes as 165 
described below. 166 
 167 
We next explored the influence of trodusquemine on fibril elongation and secondary nucleation 168 
using experiments carried out in the presence of pre-formed fibrils at neutral and acidic pH 169 
13,15,41. We studied fibril elongation by performing experiments with monomeric a-synuclein 170 
(20-100 µM) in the presence of pre-formed fibrils of the protein at a concentration of 5 µM 171 
(monomer equivalents) under quiescent conditions at pH 6.5 and 37 °C (Fig. 1c and S6); under 172 
these conditions, the kinetics of a-synuclein aggregation have been found to be dominated by the 173 
rate of fibril elongation13,15. The kinetic profiles of the aggregation reaction were then acquired 174 
in the presence of various concentrations of trodusquemine [0-10 µM]. In all cases, the ThT 175 
fluorescence was found to decrease slowly during the apparent plateau reached at the end of the 176 
reaction. This behaviour is often observed in such measurements, primarily because fibrils 177 
formed during the reaction tend to assemble into large assemblies with reduced exposed surface 178 
area available for ThT interaction13,15,41. For each trodusquemine concentration, we extracted the 179 
elongation rate through linear fits of the early time points of the kinetic traces13,15, and found that 180 
trodusquemine does not detectably influence fibril elongation (Figs. 1d and S7). We then 181 
explored the influence of trodusquemine on fibril-catalysed secondary nucleation by incubating 182 
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monomeric a-synuclein (60-100 µM) at 37 °C in the presence of pre-formed fibrils at a 183 
concentration of 50 nM (monomer equivalents) with increasing concentrations of trodusquemine 184 
(0-10 µM) under quiescent conditions at pH 4.813,15,41 (Figs. 1e,f, S8, S9). We then analyzed the 185 
change in fibril number concentration as previously described15, and found that the rate of 186 
secondary nucleation decreased significantly with increasing concentrations of trodusquemine.  187 
 188 
The observation that trodusquemine can inhibit secondary nucleation processes is likely to be 189 
associated with its ability to bind to the surfaces of amyloid fibrils, as such a situation has been 190 
found for molecular chaperones that show similar abilities44 . We therefore probed the binding of 191 
trodusquemine to a-synuclein fibrils by incubating pre-formed fibrils at a concentration of 10 192 
µM (monomer equivalents) overnight with equimolar concentrations of trodusquemine, followed 193 
by an ultracentrifugation step29. We determined the concentration of trodusquemine in the 194 
supernatant before and after incubation with fibrils using mass-spectrometry (Fig. S10), and 195 
found that approximately 70% of the trodusquemine molecules were associated with the fibrils, 196 
consistent with its ability to bind to their surfaces and inhibit the secondary nucleation of α-197 
synuclein. In summary, therefore, we observed that trodusquemine inhibits both the lipid-198 
induced initiation and the fibril-induced amplification (secondary nucleation) step, in the process 199 
of α-synuclein aggregation (Fig. 1g). This behavior can be attributed, at least in large part, to its 200 
ability to displace the protein from the surface of both lipid vesicles and fibrils. 201 
 202 
In order to exclude the probability that any contribution to the observed effects was a result of 203 
the quenching of ThT by trodusquemine, we incubated preformed α-synuclein fibrils with ThT in 204 
presence or absence of trodusquemine, and could see that the compound did not affect the ThT 205 
signal to any detectable extent (Figure S11). In addition, because it has been found in some 206 
cases that a small molecule can inhibit the aggregation by sequestering proteins in a non-specific 207 
manner as micelles or larger aggregates45, we investigated the behavior of trodusquemine itself 208 
under the conditions used here (20 mM phosphate buffer, pH 6.5, 30 °C), using 1D 1H and 2D 209 
1H diffusion ordered spectroscopy (DOSY) experiments (Figure S12-S13). The comparison of 210 
the trodusquemine intensities with those of an internal standard with the same concentration 211 
indicated that trodusquemine is very largely (>95%) monomeric under these conditions (Figure 212 
S12). Moreover, a diffusion coefficient of 2.42 • 10–10 m2 s–1, which is typical of a small 213 
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molecule of this size in an aqueous solution, was determined for trodusquemine under these 214 
conditions, ruling out its self-assembly in solution (Figure S13). This result is supported by the 215 
absence of significant effects in the elongation step described above (Figure 1), which would be 216 
decreased if the concentration of free monomeric trodusquemine were reduced. 217 
 218 
Trodusquemine suppresses the toxicity of a-synuclein oligomers in human neuroblastoma 219 
cells by inhibiting their binding to the cell membrane 220 
 221 
In an additional series of experiments we explored the effect of trodusquemine on the 222 
cytotoxicity associated with the aggregation of a-synuclein43,46,47. We prepared samples of toxic 223 
type B* oligomers based on recently developed protocols46,47 and added them to the cell culture 224 
medium of human Sh-Sy5Y neuroblastoma cells at a concentration of 0.3 µM (monomer 225 
equivalents of a-synuclein). The MTT assay, which provides a measure of cellular viability (see 226 
Methods for details), confirms previous results that these oligomers are toxic to cells (Fig. 2a). 227 
We then treated the cells with these oligomers (0.3 µM) in the presence of increasing 228 
concentrations of trodusquemine (0.03, 0.1 and 0.3 µM), and observed that the toxicity was 229 
markedly reduced, particularly at the highest trodusquemine concentration (0.3 µM) where 230 
essentially complete protection was observed (Fig. 2a). In addition, these a-synuclein oligomers 231 
(0.3 µM) in the absence of trodusquemine were shown to induce an increase in the levels of 232 
reactive oxygen species (ROS) in this cell model, indicating their ability to inflict cellular 233 
damage (Fig. 2b). Repeating the experiments with increasing concentrations of trodusquemine 234 
(0.03, 0.3 and 3.0 µM), however, resulted in a marked decrease in the degree of ROS-derived 235 
fluorescence, showing a well-defined dose dependence and virtually complete inhibition of 236 
intracellular ROS production at a protein-to-trodusquemine ratio of 1:10 (Fig. 2b). 237 
 238 
We next investigated the mechanism by which trodusquemine inhibits a-synuclein oligomer 239 
toxicity by probing the interactions between the oligomers (0.3 µM) and human SH-SY5Y cells 240 
at increasing concentrations of trodusquemine (0.03, 0.3 and 3.0 µM) using anti-a-synuclein 241 
antibodies in conjunction with confocal microscopy. The images were scanned at apical planes to 242 
detect oligomers (green) interacting with cellular surfaces (red) by confocal microscopy (Fig. 243 
2c).  Following the addition of the a-synuclein oligomers to the cell culture medium, a large 244 
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number of these species were observed to be associated with the plasma membranes of the cells, 245 
but their number was significantly and progressively decreased as the trodusquemine 246 
concentration was increased, showing a well-defined dose dependence (Fig. 2c). We have shown 247 
previously that the toxicity caused by protein oligomers, which are membrane disruptive43,48,49, 248 
correlates with the affinity of membrane binding50. This protective effect can therefore be 249 
attributed to the reduced ability of a-synuclein oligomers to interact with the cell membranes in 250 
the presence of trodusquemine. Such protection is likely to result from the ability of 251 
trodusquemine to bind to the cellular membranes and displace the oligomers from them, and 252 
potentially through its interactions with the oligomeric species themselves as suggested by the in 253 
vitro experiments on lipid binding discussed above. 254 
  255 
Trodusquemine inhibits formation of the a-synuclein inclusion in a C. elegans model of PD, 256 
and increases both fitness and longevity of the PD worms 257 
 258 
To examine whether or not trodusquemine shows the effects observed in cell cultures in a living 259 
organism, we used a well-established C. elegans model in which α-synuclein is over expressed in 260 
the large muscle cells (‘PD worms’) that shows age-dependent inclusion formation and related 261 
toxicity, which can be measured by a decrease in the number of body bends per minute (BPM), 262 
an increase in paralysis rate and a decrease in speed of movement29. As described previously for 263 
squalamine, we first carried out experiments aimed at optimizing the treatment profile of the 264 
worms29. We evaluated different treatment schedules by administering trodusquemine as a 265 
single, continuous dose either at an early stage of the life of the animals (L4 larval stage) or late 266 
in the adulthood (D5, adulthood stage) (Fig. 3a). 267 
 268 
We then investigated PD worms expressing a-synuclein fused to the yellow fluorescent protein 269 
(YFP), and also control worms expressing only YFP, in conjunction with fluorescence 270 
microscopy in order to probe the number and distribution of a-synuclein inclusions51,52. The 271 
expression of YFP in the large muscle cells of the control animals was uniform and did not lead 272 
to the formation of visible inclusions at D12 of adulthood; furthermore, the YFP expression 273 
pattern was not significantly affected by the administration of trodusquemine and was constant 274 
with age (Fig. 3b). By contrast, PD worms in the absence of trodusquemine were found to have 275 
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large numbers of inclusions at D12, with the number decreasing significantly (up to 50%) after 276 
treatment with trodusquemine either at the L4 larval stage (p < 0.001 at D12) or at D5 of 277 
adulthood (p < 0.001 at D12). Indeed, treatment of the PD worms at the L4 larval stage, prior to 278 
the appearance of a-synuclein aggregates, significantly reduced the rate of formation of visible 279 
a-synuclein inclusions as the animals progressed through adult stages (Fig. 3c). In addition, 280 
initiation of treatment of the PD worms as adults on D5, after a-synuclein inclusions had already 281 
appeared in the animals, also significantly decreased the subsequent rate of formation of 282 
inclusions as the animals aged (Fig. 3c).  283 
 284 
In an additional series of experiments, the functional behaviour of the worms was found to be 285 
correlated with the observed effects on inclusion formation.  We observed that PD worms treated 286 
at the L4 larval stage showed a strongly increased frequency of body bends per time unit (p < 287 
0.001 at D14), an increased speed of movement (p < 0.001 at D14), and a decreased rate of 288 
paralysis (p < 0.001 at D14) in comparison to untreated PD worms. Indeed, the behaviour of the 289 
PD worms treated with 10 µM trodusquemine was comparable to that of the healthy control 290 
worms (Fig. 3d). Accordingly, trodusquemine appears to share similarities in its mode of action 291 
with compounds that inhibit the primary nucleation events in protein aggregation such as 292 
squalamine29. We observed in addition, however, that PD worms treated at D5 of adulthood also 293 
showed a greatly decreased fraction of paralyzed animals (p < 0.001 at D14) in combination with 294 
increased body bends per time unit (p < 0.001 at D14) and speed of movement (p < 0.001 at 295 
D14) (Fig. 3d). Taken together, these results suggest strongly that trodusquemine has the ability 296 
to inhibit secondary nucleation as observed in vitro (Fig. 1). Thus, in this animal model of PD, 297 
trodusquemine exhibits both prophylactic and therapeutic efficacy with respect to the formation 298 
of a-synuclein aggregates. By calculating the ‘total fitness’ score, which is a linear combination 299 
of the various types of behaviour of the worms, including frequency of body bend, speed of 300 
movement and paralysis rate29, the significant increase in the health of PD worms treated with 301 
trodusquemine at L4 (p < 0.001 at D14) and D5 (p < 0.001 at D14) in comparison to untreated 302 
PD worms is clearly evident (Fig. 3e).  303 
 304 
In addition to such protective actions on the effects of aggregation, exposure of trodusquemine at 305 
either L4 (p < 0.001 at D20) or D5 (p < 0.001 at D20) significantly increased the longevity of the 306 
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PD worms, related to untreated animals (Fig. 3f). The lifespan (described here as the age at 307 
which there is the 50% mortality of the population) of untreated PD worms was about 17±1 days, 308 
similar to that of control individuals (Fig. 3f). Treatment of the PD worms at L4 extended 309 
longevity to 24±1 days, and at D5, to 20±1 days, in each case exceeding the longevity of healthy 310 
control animals. Intriguingly, trodusquemine administration also improved the survival of control 311 
animals (Fig. 3g), although to a lesser extent, suggesting that the effect of trodusquemine on 312 
lifespan is enhanced in the presence of tissue injury caused by the accumulation of a-synuclein 313 
inclusions. Longevity in C. elegans has been studied extensively and the roles of multiple 314 
pathways including insulin/insulin-like growth factor (IGF)-1 signalling, and dietary restriction, 315 
has been shown to influence lifespan53-58. Of particular significance in the context of our 316 
observations is the report that trodusquemine can stimulate regeneration in various vertebrate 317 
tissues and organs following injury, including those of adult mice, through mobilization of stem 318 
cells, with no apparent effect on the growth of uninjured tissues39. The electrostatic interactions 319 
between trodusquemine and membrane-associated phosphatidylinositol 3,4,5-triphosphate 320 
(PIP3), driven by the spermine moiety, could also play an important role in this phenomenon, as 321 
the displacement of specific PIP3 binding proteins has been shown to increase fitness and 322 
longevity in wild type and PD models in C. elegans59. Further experiments will, however, be 323 
required to define in detail how trodusquemine extends, in particular, the lifespan of the PD 324 
worms and its potential relevance to human subjects.  325 
 326 
  327 
 328 
Conclusions  329 
 330 
We have shown that the aminosterol trodusquemine inhibits the lipid-induced initiation of 331 
aggregation of a-synuclein in vitro, whereas it has no detectable effect on the rate of elongation 332 
of fibrils. As with the related aminosterol squalamine, trodusquemine inhibits the initiation of 333 
aggregation, but we have also found, however, that it inhibits the secondary nucleation of a-334 
synuclein, thereby reducing the proliferation of the aggregates. The reduction by trodusquemine 335 
of both these nucleation processes will reduce substantially the number of potentially toxic 336 
aggregates, providing an explanation for the observation of the substantial protective effects of 337 
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trodusquemine observed both in cultured cells and in a C. elegans model of PD. As with 338 
squalamine29, trodusquemine appears to be able to displace a-synuclein and its oligomers from 339 
the membrane, inhibiting both the lipid-induced initiation of the aggregation process and the 340 
ability of the oligomers to disrupt the integrity of membranes. In addition, these molecules may 341 
interact directly with the oligomers to reduce their inherent toxicity. Intriguingly, administration 342 
of trodusquemine, also extends the longevity of the PD worms, beyond even that of control 343 
animals and to an extent larger than that observed with squalamine. Taken together these results 344 
suggest that trodusquemine, which can cross the blood brain barrier, could have multiple benefits 345 
in the context of human a-synucleinopathies, ranging from an increased understanding of the 346 
nature and progression of these conditions to disease modification and tissue regeneration.  347 
 348 
 349 
 350 
Materials and Methods 351 
 352 
Reagents. 1,2-Dimyristoyl-sn-glycero-3-phospho-L-serine (sodium salt; DMPS) was purchased 353 
from Avanti Polar Lipids (Alabaster, AL, USA). Trodusquemine (as the chloride salt) was 354 
synthesized as previously described31 and was greater than 97% pure as evaluated by mass 355 
spectrometry. Trodusquemine powder was used immediately after dilution.   356 
 357 
Protein expression and lipid preparation. Wild type human a-synuclein was recombinantly 358 
expressed and purified as described previously14,15. For concentration measurements, we used an 359 
extinction coefficient of 5600 M−1 cm-1 at 275 nm. After the final size-exclusion chromatography 360 
step (20 mM phosphate buffer, pH 6.5), the protein was snap frozen in liquid nitrogen in the 361 
form of 1 ml aliquots and stored at -80 ◦C. These aliquots were used without further treatment, 362 
except for the aggregation experiments at low pH where the pH was adjusted to the desired value 363 
with small volumes of 100 mM NaOH or HCl. The lipids were dissolved in 20 mM phosphate 364 
buffer (NaH2PO4/Na2HPO4), pH 6.5, 0.01% NaN3 and stirred at ca. 45 °C for 2 h. The solution 365 
was then frozen and thawed five times using dry ice and a water bath at 45 °C. The preparation 366 
of vesicles was carried out on ice by means of sonication (3 x 5 min, 50% cycles, 10% maximum 367 
power on ice) using a Bandelin Sonopuls HD 2070 (Bandelin, Berlin, Germany). After 368 
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centrifugation, the sizes of the vesicles were checked using dynamic light scattering (Zetasizer 369 
Nano ZSP, Malvern Instruments, Malvern, UK) and were shown to consist of a distribution 370 
centered on a diameter of 20 nm.  371 
 372 
Circular dichroism (CD) spectroscopy. 373 
Data Acquisition: Samples were prepared as described previously29 by incubating 5 µM a-374 
synuclein with 250 µM DMPS vesicles in 20 mM phosphate buffer, pH 6.5, 0.01% NaN3 and 0-375 
50 µM trodusquemine. Far-UV CD spectra were recorded on a JASCO J-810 instrument (Tokyo, 376 
Japan) equipped with a Peltier thermally controlled cuvette holder at 30 °C. Quartz cuvettes with 377 
path lengths of 1 mm were used, and the CD signal was measured in each case at 222 nm by 378 
averaging 60 individual measurements with a bandwidth of 1 nm, a data pitch of 0.2 nm, a 379 
scanning speed of 50 nm/min and a response time of 1 s. The signal of the buffer containing 380 
DMPS and the different concentrations of trodusquemine was subtracted from that of the protein. 381 
Data Analysis: The concentration of a-synuclein bound to DMPS vesicles ([𝛼#]) when 5 µM a-382 
synuclein was incubated in the presence of 250 µM DMPS and increasing concentrations of 383 
trodusquemine ([𝑇]) was calculated from the CD signal measured at 222 nm as described 384 
previously14. The change in [𝛼#] with increasing [𝑇] was then analyzed as described previously29 385 
using the standard solution of the cubic equation: 386 
 387 𝐾',) = ([',-.]/01[23]/04[)3])([)]/[)3])04[)3]                      Eq. 1 388 
[𝑇#] = [',-.]/04[)3]678,101601[2]/9:01([)3]04[2]/[',-.][2])6;[',-.]/[)3]04678,101601[2]<=>01       Eq. 2 389 
where 𝐾',) and 𝐾',2 are the binding constant of a-synuclein and trodusquemine, respectively; 390 𝐿) and 𝐿2 are the stoichiometries at which DMPS binds to a-synuclein and trodusquemine, i.e. 391 
the number of lipid molecules interacting with one molecule of either a-synuclein or 392 
trodusquemine, respectively; [𝐷𝑀𝑃𝑆],  [𝛼] and [𝑇] are the total concentrations of DMPS, a-393 
synuclein and trodusquemine, respectively; [𝛼#] and [𝑇#] are the concentrations of a-synuclein 394 
and trodusquemine bound to DMPS vesicles, respectively. The best fit is shown in Figure S2 395 
with 𝐾',2 = 1.62 x 10-8 M and 𝐿2 = 5.1.  Further details of the analysis see the Supplementary 396 
Materials. 397 
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 398 
Dynamic light scattering (DLS) measurements. 399 
Measurements of vesicle size distributions in the absence and presence of the indicated 400 
concentrations of trodusquemine were carried out by dynamic light scattering (DLS) experiments 401 
using a Zetasizer Nano ZSP Instrument (Malvern Instruments, Malvern, UK) with backscatter 402 
detection at a scattering angle of 173°. The concentration of the vesicles was 0.1 mM in 403 
phosphate buffer (20 mM, pH 6.5) and the experiments were carried out at a temperature of 404 
25 °C. 405 
 406 
Aggregation kinetics in the presence of lipid vesicles. 407 
Data Acquisition: a-Synuclein was incubated at a concentration of 20-100 µM in 20 mM sodium 408 
phosphate, pH 6.5, 0.01% NaN3, in the presence of 50 µM ThT, 100 µM DMPS vesicles and 409 
increasing concentrations of trodusquemine (0 to 10 µM) 29. The stock solution of trodusquemine 410 
was prepared by dissolving the molecule in 20 mM phosphate buffer to a final concentration of 411 
100 µM. The change in the ThT fluorescence signal with time was monitored using a Fluostar 412 
Optima or a Polarstar Omega (BMG Labtech, Aylesbury, UK) fluorimeter under quiescent 413 
conditions at 30 °C29. Corning 96-well plates with half-area (black/clear bottom) nonbinding 414 
surfaces (Sigma Aldrich, St. Louis, MO, USA) were used for each experiment.  415 
Data Analysis: The early times of the aggregation curves of α-synuclein in the presence of 416 
DMPS and different concentrations of trodusquemine were fitted using the one-step nucleation 417 
model described previously14 and the following equation: 418 
 419 𝑀(𝑡) = 	 7FGHI(J)KHLGK[',-.]M=>;7F6I(J)<04             Eq. 3 420 
 421 
where 𝑡 is the time, 𝑀(𝑡)is the aggregate mass, 𝑚(0) is the free monomer concentration, 𝐾, is 422 
the saturation constant of the elongation process (125 µM14, 𝑘Q and 𝑘6 are the rate constants of 423 
nucleation and elongation, respectively, and [',-.]04 	is the concentration of protein-binding sites at 424 
the surface of the membrane. First, the early times of the kinetic traces measured for α-synuclein 425 
in the presence of 100 µM DMPS and in the absence of trodusquemine were fitted using Eq. 3, 426 
with 𝑘Q𝑘6, and 𝑛 being global fitting parameters (see fits in Fig. S4a). The global fit yields 𝑛 = 427 
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0.745, and 𝑘Q𝑘6 = 8.6 x 10-3 M-(n+1).s-2. We then fixed 𝑛 to 0.745 and fitted the early times of the 428 
data in the presence of trodusquemine using Eq. 3, with 𝑘Q𝑘6, being the only global fitting 429 
parameters (see Fig. S4 b-f). This way we obtain the effective rate of lipid-induced aggregation 430 
of α-synuclein relative to that in the absence of trodusquemine, at all α-synuclein and 431 
trodusquemine concentrations (see Fig. S5): 432 𝑟TUU = GKGHVGKGH                  Eq. 4 433 
where 𝑘Q𝑘6W is the product of the nucleation and elongation rate constants at a given 434 
[trodusquemine]:[α-synuclein] ratio. If trodusquemine were to inhibit α-synuclein lipid-induced 435 
aggregation via the same mechanism as that reported previously for squalamine29 and b-436 
synuclein14,41, the effective rate should scale with a power of the coverage, i.e.  𝑟TUU = 𝜃)Q3, 437 
where 𝜃) is the fractional coverage of a lipid vesicle in α-synuclein and 𝑛# is the reaction order 438 
of lipid-induced aggregation with respect to 𝜃). In the absence of trodusquemine, 𝜃) = 1, as we 439 
are in a regime where the vesicles are saturated. We determined 𝜃) for the different 440 
[trodusquemine]:[α-synuclein] ratios used in our study using a simplified competitive binding 441 
model with the values of 𝐾',2 and 𝐿2 determined in this study and 𝐾',) and 𝐿) determined 442 
previously14, using 𝑛# = 5.5, as determined previously29,41 and the following equations: 443 
 444 𝜃) = [)3]04[',-.]                          Eq. 5 445 
 446 
            447 [𝛼#] = [',-.]04Z/[',-.]01/[)]0401/0401[2]Z>;04= Z/0401<   448 
+9:[)][',-.]01;04= Z/0401<6([',-.]016[)]0401/[',-.]04Z60401[2]Z)=>;04= Z/0401<          Eq. 6 449 
where 𝜅 = 78,478,1 . 450 
 451 
We found that the values of 𝑟TUU obtained at different [trodusquemine]:[α-synuclein] ratios do 452 
not scale simply as 𝜃)Q3 , with the coverage 𝜃) calculated using Eqs. 5-6 at the corresponding 453 
ratios, suggesting that trodusquemine inhibits α-synuclein lipid-induced aggregation via a more 454 
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complex mechanism than that described for squalamine (see Fig. S5), perhaps resulting from a 455 
direct interaction with the oligomeric species resulting in an inhibition of their inherent toxicity. 456 
 457 
Seed fibril formation. Seed fibrils were produced as previously described15,41. Briefly, we 458 
incubated 500 µl solutions of a-synuclein at concentrations between 500 and 800 µM in 20 mM 459 
phosphate buffer at pH 6.5 for 48 - 72 h at ca. 40 °C with maximal stirring with a Teflon bar on 460 
an RCT Basic Heat Plate (IKA, Staufen, Germany). The fibrils were divided into aliquots, frozen 461 
in liquid N2 and stored at -80 °C until required. For aggregation experiments, the seed fibrils 462 
were diluted to 200 µM monomer equivalents into the specific buffer to be used in the 463 
experiment and sonicated 3 times for 10 s using a Bandelin Sonopuls HD 2070 probe sonicator 464 
(Bandelin, Berlin, Germany), using 10% maximum power and 30% cycles.  465 
 466 
Seeded aggregation kinetics. The seeded experiments were performed as described 467 
previously15,41. Briefly, to probe fibril elongation, preformed seeds fibrils (5 µM monomer 468 
equivalents) were added to solutions of monomeric α-synuclein (20-100 µM) in 20 mM 469 
phosphate buffer (pH 6.5) with 50 µM ThT, under quiescent conditions, at 37 °C. For 470 
experiments to probe the influence on secondary nucleation, seeds (50 nM monomer equivalents) 471 
were added to monomeric α-synuclein (60-100 µM) in 20 mM phosphate buffer (pH 4.8) and in 472 
the presence of 50 µM ThT, under quiescent conditions, also at 37 °C. The increase in ThT 473 
fluorescence was monitored in low binding, clear-bottomed half-area Corning 96 well plates 474 
(Sigma Aldrich, St. Louis, MO, USA) that were sealed with tape, and using either a Fluostar 475 
Optima, Polarstar Omega (BMG Labtech, Aylesbury, UK) or an M1000 (Tecan Group Ltd., 476 
Männedorf, Switzerland) fluorescence plate-reader in bottom reading mode. All experiments 477 
were performed under quiescent conditions (i.e. without shaking).  478 
 479 
Data analysis. Data were analyzed as previously described15,41. 480 
 481 
Mass spectrometry. Experiments were carried out as previously described29. Briefly, fibrils of a-482 
synuclein at a concentration of 10 µM (monomer equivalents) were incubated with 10 µM 483 
trodusquemine in 20 mM Tris, pH 7.4, 100 mM NaCl overnight under quiescent conditions at 484 
room temperature. The samples were then centrifuged at 100.000g for 30 min and the 485 
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supernatant then removed for analysis. Samples for the analysis by mass spectrometry were 486 
prepared as described29 and the experiments were run using a Waters Xevo G2-S QTOF 487 
sprectrometer (Waters Corporation, MA, USA). 488 
 489 
 490 
Nuclear magnetic resonance (NMR) spectroscopy. H2O was removed from trodusquemine by 491 
three cycles of lyophilisation and the compound was resolvated in 100% D2O (Sigma Aldrich). It 492 
was then diluted into 20 mM phosphate buffer, pH 6.5 in 100% D2O to a final concentration of 493 
10 µM. All NMR measurements were performed at 30 °C on a Bruker AVANCE-500 494 
spectrometer, operated at a 1H frequency of 500.13 MHz, equipped with a cryogenic probe. 495 
Measurements of diffusion coefficients were performed using 2D 1H diffusion 496 
ordered spectroscopy (DOSY) experiments60. These spectra were acquired using the standard 497 
‘ledbpgppr2s’ Bruker pulse program, using a bipolar gradient pulse pair-stimulated echo 498 
sequence incorporating a longitudinal eddy current delay61, with a diffusion time of (∆) 100 ms, 499 
a gradient pulse length (δ) of 3 ms, and increasing the gradient strength between 4.8 < g < 38.5 500 
Gcm-1. The values of (∆) and (δ) were chosen based on measurements of 1.5 mM trodusquemine 501 
in water, in which it is very soluble. To remove the signal from residual H2O in the sample, 502 
presaturation was used. Data for 1.5 mM trodusquemine in 100% D2O were collected with 8 503 
scans and 16 gradient steps, while data for 10 µM trodusquemine in 20 mM phosphate buffer 504 
were collected with 400 scans and 12 gradient steps. Individual rows of the pseudo-2D diffusion 505 
data were phased and baseline corrected. DOSY spectra were processed using the TopSpin 2.1 506 
software (Bruker). The diffusion dimension was generated using the intensities (I) of resolved 507 
peaks between 3.0 and -0.5 ppm according to the Stejskal-Tanner equation62: 508 𝐼𝐼J = 𝑒/_=`=a='(∆/ac) 509 
where 𝛾 is the gyromagnetic ratio and using the DynamicsCenter 2.5.3 software (Bruker). 1D 1H 510 
NMR spectra of 10 µM trodusquemine alone in 20 mM phosphate buffer, pH 6.5, 30 °C, made 511 
up in 100% D2O or in the presence of equimolar 4,4-dimethyl-4-silapentane-1-sulfonic acid 512 
(DSS, Sigma Aldrich) as an internal concentration standard. These spectra were acquired using 513 
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the standard ‘noesypr1d’ Bruker pulse program with presaturation remove the signal from 514 
residual H2O in the sample. Spectra were processed using TopSpin 2.1. 515 
 516 
ThT binding to trodusquemine. Pre-formed fibrils of α-synuclein (5 µM) were added to 517 
monomeric α-synuclein at a concentration of 100 µM and incubated in 96-well half-area, low-518 
binding polyethylene glycol coating plate (Corning 3881, Kennebuck ME, USA) at 37 °C in 20 519 
mM phosphate buffer (pH 6.5) under quiescent conditions for 24 h. Then, the resulting longer 520 
fibrils were diluted to 50 µM α-synuclein with 50 µM ThT and the absence of presence of the 521 
indicated concentration of trodusquemine in 20 mM phosphate buffer (pH 6.5) and incubated at 522 
37 °C for 12 h. The fluorescence intensity of the different samples was measured using a plate 523 
reader (Fluostar Optima, BMG Labtech, Ortenberg, Germany). 524 
 525 
Preparation of oligomers. Samples of a-synuclein type B* oligomers were prepared as 526 
previously described47. Briefly, monomeric a-synuclein was lyophilized in Milli-Q water and 527 
subsequently resuspended in PBS, pH 7.4, to give a final concentration of ca. 800 µM (12 528 
mg/mL). The resulting solutions were passed through a 0.22 µm cut-off filter before incubation 529 
at 37 °C for 20 - 24 h under quiescent conditions47. Very small amounts of fibrillar species 530 
formed during this time were removed by ultracentrifugation for 1h at 90,000 rpm (using a TLA-531 
120.2 Beckman rotor, 288,000 g). Excess monomeric protein and any small oligomeric species 532 
were then removed by multiple cycles of filtration using 100 kDa cut-off membranes. The final 533 
concentration of the prepared oligomers was estimated using e275 = 5600 M−1 cm−1. 534 
 535 
Neuroblastoma cell cultures. Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA, 536 
USA) were cultured in DMEM, F-12 HAM with 25 mM HEPES and NaHCO3 (1:1) and 537 
supplemented with 10% FBS, 1 mM glutamine and 1.0% antibiotics. Cell cultures were 538 
maintained in a 5% CO2 humidified atmosphere at 37 °C and grown until they reached 80% 539 
confluence for a maximum of 20 passages63. 540 
 541 
MTT reduction assay. a-Synuclein oligomers (0.3 µM monomer equivalents) were incubated 542 
without or with increasing concentrations (0.03, 0.1 and 0.3) of trodusquemine for 1 h at 37 °C 543 
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under shaking conditions and then added to the cell culture medium of SH-SY5Y cells seeded in 544 
96-well plates for 24 h. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 545 
(MTT) reduction assay was performed as previously described64. 546 
 547 
Measurement of intracellular ROS. SH-SY5Y cells were seeded on glass coverslips and treated 548 
for 15 min with a-synuclein oligomers (0.3 µM) and increasing concentrations (0.03, 0.3 and 3 549 
µM) of trodusquemine. After incubation, the cells were washed with PBS and loaded with 10 550 
µM 2’,7’-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) (Life Technologies, CA, USA) 551 
as previously described63. The fluorescence of the cells was then analyzed by means of a TCS 552 
SP5 scanning confocal microscopy system (Leica Microsystems, Mannheim, Germany) 553 
equipped with an argon laser source, using the 488 nm excitation line. A series of 1.0 µm thick 554 
optical sections (1024 x 1024 pixels) was taken through the cells for each sample using a Leica 555 
Plan Apo 63 oil immersion objective.  556 
 557 
Oligomer binding to cellular membranes. SH-SY5Y cells were seeded on glass coverslips and 558 
treated for 15 min with a-synuclein oligomers (0.3 µM) and increasing concentrations (0.03, 0.3 559 
and 3 µM) of trodusquemine. After incubation, the cells were washed with PBS and 560 
counterstained with 5.0 µg/ml Alexa Fluor 633-conjugated wheat germ agglutinin (Life 561 
Technologies, CA, USA) to label fluorescently the cellular membrane29. After washing with 562 
PBS, the cells were fixed in 2% (w/v) buffered paraformaldehyde for 10 min at room 563 
temperature (20 °C). The presence of oligomers was detected with 1:250 diluted rabbit 564 
polyclonal anti-a-synuclein antibodies (Abcam, Cambridge, UK) and subsequently with 1:1000 565 
diluted Alexa Fluor 488-conjugated anti-rabbit secondary antibodies (Life Technologies, CA, 566 
USA). Fluorescence emission was detected after double excitation at 488 nm and 633 nm by the 567 
scanning confocal microscopy system described above and three apical sections were projected 568 
as a single composite image by superimposition. 569 
 570 
C. elegans media. Standard conditions were used for the propagation of C. elegans65. Briefly, the 571 
animals were synchronized by hypochlorite bleaching, hatched overnight in M9 (3 g/l KH2PO4, 6 572 
g/l Na2HPO4, 5 g/l NaCl, 1 µM MgSO4) buffer, and subsequently cultured at 20 °C on nematode 573 
growth medium (NGM) plates (1 mM CaCl2, 1 mM MgSO4, 5 µg/ml cholesterol, 250 µM 574 
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KH2PO4, pH 6, 17 g/L Agar, 3g/l NaCl, 7.5g/l casein) seeded with the E. coli strain OP50. 575 
Saturated cultures of OP50 were grown by inoculating 50 mL of LB medium (10g/l tryptone, 576 
10g/l NaCl, 5g/l yeast extract) with OP50 cells and incubating the culture for 16 h at 37 °C. 577 
NGM plates were seeded with bacteria by adding 350 µl of saturated OP50 cells to each plate 578 
and leaving the plates at 20 °C for 2-3 days. On day 3 after synchronization, the animals were 579 
placed on NGM plates containing 75 µM 5-fluoro-2'deoxy-uridine (FUDR). 580 
 581 
Strains. The following strains were used: zgIs15 [P(unc-54):: a-syn::YFP]IV (OW40), in which 582 
a-synuclein fused to YFP relocates to inclusions, which are visible as early as day 2 after 583 
hatching and increase in number and size during the ageing of the animals, up to late adulthood 584 
(Day 17)29,66. and rmIs126 [P(unc-54)Q0::YFP]V (OW450). In OW450, YFP alone is expressed 585 
and remains diffusely localized throughout ageing29,66.  586 
 587 
Trodusquemine-coated plates. Plates were prepared as previously described29. Briefly, aliquots 588 
of NGM media were autoclaved, poured and seeded with 350 µL OP50 culture, and grown 589 
overnight at RT. After incubating for up to 3 d at room temperature, aliquots of trodusquemine 590 
dissolved in water at different concentrations were added. NGM plates containing FUDR (75 591 
µM, unless stated otherwise) were seeded with aliquots of the trodusquemine dissolved in water, 592 
at the appropriate concentration. The plates were then placed in a laminar flow hood at room 593 
temperature to dry and the worms were transferred to plates coated with trodusquemine at larval 594 
stage L4. 595 
 596 
Automated motility assay. All C. elegans populations were cultured at 20 °C and 597 
developmentally synchronized from a 4 h egg-lay. At 64-72 h post egg-lay (time zero) 598 
individuals were transferred to FUDR plates, and body movements were assessed over the times 599 
indicated. At different ages, the animals were washed off the plates with M9 buffer and spread 600 
over an OP-50 unseeded 6 cm plate, after which their movements were recorded at 30 fps using a 601 
recently developed microscopic procedure for 30 s or 1 min29. Up to 200 animals were counted 602 
in each experiment unless otherwise stated. One experiment that is representative of the three 603 
measured in each series of experiments is shown and videos were analyzed using a custom made 604 
tracking code29,67.   605 
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 606 
Lifespan assays. Lifespan analysis was carried out as previously described68. On day 4 after 607 
synchronization the animals were placed on NGM plates containing FUDR. On L4 or D5, they 608 
were manually transferred to plates seeded with 10 µM trodusquemine. Experiments were 609 
performed at 20 °C. Lifespan experiments were performed with 75 animals per condition. At 610 
each time point, the number of surviving animals, determined by movement and response to nose 611 
touch, was counted. Animals that crawled out of the plates during the assay were excluded. 612 
Three independent experiments were carried out in each case and one representative is shown. 613 
Analysis was performed using GraphPad Prism (GraphPad Software).  614 
 615 
Quantification of inclusions. Individual animals were mounted on 2% agarose pads, containing 616 
40 mM NaN3 as an anesthetic, on glass microscope slides for imaging29. Only the frontal region 617 
of the worms was considered29,66. The numbers of inclusions in each animal were quantified 618 
using a Leica MZ16 FA fluorescence dissection stereomicroscope (Leica Microsystems, Wetzlar, 619 
Germany) at a nominal magnification of 20X or 40X, and images were acquired using an 620 
Evolve 512 Delta EMCCD Camera, with high quantum efficiency (Photometrics, Tucson, AZ, 621 
USA). Measurements on inclusions were performed using ImageJ software29. All experiments 622 
were carried out in triplicate and the data from one representative experiment are shown in the 623 
figure. The Student's t-test was used to calculate p values, and all tests were two-tailed unpaired 624 
unless otherwise stated. At least 50 animals were examined per condition, unless stated 625 
otherwise29. 626 
 627 
 628 
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 957 
 958 
Figure 1. Trodusquemine inhibits both the lipid-induced initiation and the fibril-induced 959 
amplification steps in a-synuclein aggregation in vitro. (a) Change in ThT fluorescence 960 
intensity when 100 µM monomeric a-synuclein was incubated in the presence of 100 µM DMPS 961 
vesicles and 50 µM ThT in 20 mM phosphate buffer (pH 6.5) under quiescent conditions at 30 962 
°C. Trodusquemine was added to the solutions at increasing concentrations (black: 0 µM, dark 963 
blue: 1 µM, green: 2.5 µM, purple: 5 µM, red: 10 µM); two independent traces are shown for 964 
each concentration. (b) Relative rates of lipid-induced aggregation. The data were analyzed by 965 
globally fitting the early times of the kinetic traces using a single-step nucleation model15,41 (see 966 
Materials and Methods for details). (c) Change in ThT fluorescence intensity when 100 µM 967 
 
31 
monomeric a-synuclein was incubated in the presence of 5 µM pre-formed fibrils (monomer 968 
equivalents) and 50 µM ThT in 20 mM phosphate buffer (pH 6.5) under quiescent conditions at 969 
37 °C. Increasing concentrations of trodusquemine were added to the solution (colours as in 970 
panel a) and two independent traces are shown for each concentration. (d) Effects of 971 
trodusquemine on the relative rates of fibril elongation. The rates of elongation were extracted 972 
through linear fits to the early time points of the kinetic traces shown in (c)13,15,41. (e) Change in 973 
ThT fluorescence when 100 µM monomeric a-synuclein was incubated in the presence of 50 nM 974 
pre-formed fibrils and 50 µM ThT in 20 mM phosphate buffer (pH 4.8) at 37 °C under quiescent 975 
conditions. Trodusquemine was added at different concentrations (colours as in panel (a); two 976 
independent traces are shown for each concentration. (f) Effects of trodusquemine on the relative 977 
rates of fibril amplification. The rates were analyzed by determining the change in fibril number 978 
concentration at the half time of the aggregation reaction15,41. (g) Schematic representation of the 979 
effects of trodusquemine on lipid-induced aggregation and fibril amplification. 980 
 981 
 982 
 983 
 984 
 985 
 986 
 987 
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 988 
Figure 2. Trodusquemine suppresses the toxicity of a-synuclein oligomers in human 989 
neuroblastoma SH-SY5Y cells by inhibiting their binding to cell membranes. (a) Type B* 990 
a-synuclein oligomers were resuspended in the cell culture medium at a concentration of 0.3 µM 991 
(monomer equivalents), incubated with or without different concentrations (0.03, 0.1 and 0.3 992 
µM) of trodusquemine for 1 h at 37 °C under shaking conditions, and then added to the cell 993 
culture medium of SH-SY5Y cells for 24 h to test the ability of the cells to reduce MTT. 994 
Experimental errors are S.E.M. **P ≤ 0.01, and ***P ≤ 0.001, respectively, relative to untreated 995 
cells. °°P ≤ 0.01 and °°°P ≤ 0.001, respectively, relative to cells treated with a-synuclein 996 
oligomers. (b) Top panel: Representative confocal scanning microscope images of SH-SY5Y 997 
:
:
:
 
33 
cells showing the levels of intracellular ROS following a 15 min incubation with 0.3 µM a-998 
synuclein type B* oligomers (monomer equivalents) in the absence or presence of 0.03, 0.3 and 999 
3.0 µM trodusquemine. The green fluorescence arises from the CM-H2DCFDA probe reacts with 1000 
ROS. Lower panel: quantification. * and ° symbols as in panel A. (c) Representative confocal 1001 
scanning microscopy images of the apical sections of SH-SY5Y cells treated for 15 min with a-1002 
synuclein of type B* oligomers (0.3 µM monomer equivalents) and different concentrations 1003 
(0.03, 0.3 or 3.0 µM) of trodusquemine (left panels). Red and green fluorescence indicate the cell 1004 
membranes and the a-synuclein oligomers, respectively.  Right: quantification of oligomer 1005 
binding to the cells as fraction of the cells treated with oligomers (right panel). °° and °°° 1006 
symbols as in panel A. 1007 
 1008 
 1009 
 1010 
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 1011 
 1012 
Figure 3. Treatment with trodusquemine reduces the quantity of a-synuclein aggregates 1013 
and improves fitness in C. elegans PD model.  (a) Trodusquemine was administered to the PD 1014 
worms at either the L4 larval stage or at D5 of adulthood. (b) Representative images showing the 1015 
effects of trodusquemine on PD worms expressing a-synuclein fused to yellow fluorescent 1016 
protein (YFP). Worms expressing only YFP in the large muscle cells were used as controls. For 1017 
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every experiment N=50. The images shown are representative of day 12 of adulthood. The scale 1018 
bar indicates 80 µm. (c) Effects of trodusquemine on inclusion formation in PD worms at 7, 9 1019 
and 12 days of adulthood respectively. In all panels, the experimental errors refer to SEM. (d) 1020 
Behavioural map showing the effect of trodusquemine on three phenotypic readouts of worm 1021 
fitness, i.e. paralysis rate, bends per minute (BPM) and speed of swimming, at the indicated days 1022 
of adulthood. For every time-point N=500. (e) Total fitness score quantification29, following 1023 
treatment with trodusquemine. For every time-point N=500. (f-g) Effects following the treatment 1024 
with trodusquemine on PD (f) and wild type (g) worm survival. For every condition N=75.  1025 
 1026 
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 1029 
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